Targeted treatments in advanced renal cell carcinoma: Focus on Axitinib

Elena Verzoni, Paolo Grassi, Isabella Testa, Roberto Iacovelli, Pamela Biondani, Enrico Garanzini, Filippo De Braud, Giuseppe Procopio

Research output: Contribution to journalArticlepeer-review


Antiangiogenesis options have evolved rapidly in the last few years, with an increasing number of agents currently approved by the US Food and Drug Administration and European Medicines Agency. Angiogenesis inhibitors have been shown to be very effective for the treatment of metastatic renal cancer cell. Axitinib is a third-generation inhibitor of vascular endothelial growth factor receptor and is currently being developed for the treatment of various malignancies. The pharmacokinetic properties of axitinib may have a selective therapeutic effect, with minimal adverse reactions and enhanced safety. In a large Phase III study of previously treated patients with metastatic renal cell carcinoma, axitinib achieved a longer progression-free survival than sorafenib with an acceptable safety profle and good quality of life. This review focuses on the pharmacology, pharmacokinetics, and clinical activity of axitinib in the current treatment of renal cell carcinoma. The role of axitinib in the adjuvant and/or neoadjuvant setting needs to be evaluated in further clinical trials.

Original languageEnglish
Pages (from-to)107-116
Number of pages10
JournalPharmacogenomics and Personalized Medicine
Issue number1
Publication statusPublished - Mar 27 2014


  • Angiogenesis
  • Axitinib
  • Renal cell carcinoma
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Targeted treatments in advanced renal cell carcinoma: Focus on Axitinib'. Together they form a unique fingerprint.

Cite this